Research Paper Volume 12, Issue 18 pp 17902—17920

Figure 5. ADAM17 is a target gene of miR-338-3p. (A) Venn diagrams show the common potential target of miR-338-3p in three bioinformatics software (TargetScan, miRTarBase and picTar). (B) Graphical representation of the potential binding sites between miR-338-3p and ADAM17. The relative luciferase activity was tested after co-transfection with ADAM17-Wt, ADAM17-Mut and miR-338-3p. ^**P<0.01 compared with miR-NC + ADAM17-Wt. (C) qRT-PCR analysis of ADAM17 expression in 56 paired human NSCLC tissues and the adjacent non-cancerous tissues. ^**P<0.01 compared with non-cancerous. (D) Correlation between ADAM17 and miR-338-3p was measured by Pearson’s correlation curve. (E) Correlation between ADAM17 and SBF2-AS1 was measured by Pearson’s correlation curve. (F) The expression of ADAM17 in A549 transfected with miR-338-3p was detected using immunofluorescence staining. (G) The expression of ADAM17 in H1975 transfected with miR-338-3p inhibitor was detected using immunofluorescence staining. (H) The expression of ADAM17 in A549 transfected with si-SBF2-AS1 was detected using western blotting. (I) The expression of ADAM17 in H1975 transfected with SBF2-AS1 overexpression plasmid was detected using western blotting. The data are presented as the mean ± SD. All in vitro data are representative of three independent experiments. ^**P<0.01 compared with si-Con or Vector.